Загрузка компании
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T $A+
JNJJohnson & Johnson688,6B $A+
MRKMerck & Co., Inc.364,3B $A
NVSNovartis AG306,3B $A
AMGNAmgen Inc.251,9B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 окт. 2026 г.CBGraded C, now B
MCKMckesson Corporation4 нояб. 2026 г.BAGraded B, now A
CVSCVS Health Corp4 нояб. 2026 г.BAGraded B, now A
EWEdwards Lifesciences Corporation4 нояб. 2026 г.BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 окт. 2026 г.CAGraded C, now A
На чём зарабатывает
- Sales of prescription medicines for diabetes, obesity and other conditions
Конкурирует с
Что продаёт3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
Кто покупает3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
На чём держится и что может это сломать
От чего зависит бизнес
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
Что может пойти не так
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
Полная финансовая отчётность →
О компании Novo Nordisk A/S
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- Штаб-квартира
- Bagsværd, Denmark
- Год основания
- 1923
- Сотрудников
- around 66,700 (Q2 2026, medium)
- Торгуется на
- New York Stock Exchange
- Конец финансового года
- December 31
Построено по собственной отчётности Novo Nordisk A/S, поданной в Комиссию по ценным бумагам и биржам США (SEC). Цифры — как отчиталась компания, история на акцию пересчитана на сегодняшнюю базу. Эта компания отчитывается в DKK. Цифры пересчитаны в доллары США по курсу 1,00 $ = 6,7640 DKK — текущему — и он применён ко всем периодам одинаково, поэтому рост и маржа принадлежат компании, а не обменному курсу. Это описание бизнеса — не инвестиционная рекомендация и не совет что-либо покупать или продавать.
